Search details
1.
Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.
J Infect Dis
; 229(4): 1068-1076, 2024 Apr 12.
Article
in English
| MEDLINE | ID: mdl-37673423
2.
Safety and Immunogenicity of Accelerated Heterologous Two-dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.
Clin Infect Dis
; 2024 Apr 24.
Article
in English
| MEDLINE | ID: mdl-38657084
3.
Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.
J Infect Dis
; 227(2): 268-277, 2023 01 11.
Article
in English
| MEDLINE | ID: mdl-35776140
4.
Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
J Infect Dis
; 226(4): 595-607, 2022 09 04.
Article
in English
| MEDLINE | ID: mdl-32939546
5.
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone.
Emerg Infect Dis
; 28(3): 734-738, 2022 03.
Article
in English
| MEDLINE | ID: mdl-35202536
6.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
PLoS Med
; 19(1): e1003865, 2022 01.
Article
in English
| MEDLINE | ID: mdl-35015777
7.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
PLoS Med
; 18(10): e1003813, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34714820
8.
Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya.
J Infect Dis
; 220(1): 57-67, 2019 06 05.
Article
in English
| MEDLINE | ID: mdl-30796816
9.
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.
J Infect Dis
; 220(1): 46-56, 2019 06 05.
Article
in English
| MEDLINE | ID: mdl-30796818
10.
A Tandem Cycling Program: Feasibility and Physical Performance Outcomes in People With Parkinson Disease.
J Neurol Phys Ther
; 40(4): 223-9, 2016 10.
Article
in English
| MEDLINE | ID: mdl-27576091
11.
Starting a Fee-Based Systematic Review Service.
Med Ref Serv Q
; 35(3): 266-73, 2016.
Article
in English
| MEDLINE | ID: mdl-27391177
12.
Vital signs: seat belt use among long-haul truck drivers--United States, 2010.
MMWR Morb Mortal Wkly Rep
; 64(8): 217-21, 2015 Mar 06.
Article
in English
| MEDLINE | ID: mdl-25742382
13.
An Analysis of Rescue Medication Utilization from a 3-Month, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Chronic Low Back Pain Treated with Single-Entity, Twice-Daily, Extended-Release Hydrocodone.
Pain Med
; 16(12): 2338-43, 2015 Dec.
Article
in English
| MEDLINE | ID: mdl-26301791
14.
Overview of the National Occupational Mortality Surveillance (NOMS) system: leukemia and acute myocardial infarction risk by industry and occupation in 30 US states 1985-1999, 2003-2004, and 2007.
Am J Ind Med
; 58(2): 123-37, 2015 Feb.
Article
in English
| MEDLINE | ID: mdl-25603936
15.
Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.
Pain Med
; 15(6): 975-85, 2014 Jun.
Article
in English
| MEDLINE | ID: mdl-24517082
16.
Obesity and other risk factors: the national survey of U.S. long-haul truck driver health and injury.
Am J Ind Med
; 57(6): 615-26, 2014 Jun.
Article
in English
| MEDLINE | ID: mdl-24390804
17.
Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.
Hum Vaccin Immunother
; 20(1): 2327747, 2024 Dec 31.
Article
in English
| MEDLINE | ID: mdl-38523332
18.
Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial.
Lancet Infect Dis
; 2024 Mar 26.
Article
in English
| MEDLINE | ID: mdl-38552653
19.
Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen.
PLoS Negl Trop Dis
; 18(4): e0011500, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38603720
20.
Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study.
Vaccines (Basel)
; 12(2)2024 Feb 17.
Article
in English
| MEDLINE | ID: mdl-38400193